The positive safety review from the DSMB enables the trial to move forward as planned, with an estimated completion date in December 2023
mRNA-1345 demonstrated vaccine efficacy of 83.7% against RSV lower respiratory tract disease, defined by 2 or more symptoms in older adults
Advancement to Phase 3 is a major milestone for SAB’s unique DiversitAb immunotherapy platform that produces fully human polyclonal antibodies without human donors
This is the world’s first Covid=19 DNA vaccine developed in partnership with DBT-BIRAC
ZyCoV-D had already exhibited a robust immunogenicity and tolerability and safety profile in the adaptive Phase I/II clinical trials
Subscribe To Our Newsletter & Stay Updated
